2:10 PM
 | 
Jan 10, 2018
 |  BC Extra  |  Clinical News

Novavax gains on DSMB analysis for RSV vaccine

Novavax Inc. (NASDAQ:NVAX) jumped $0.79 (59%) to $2.12 on Wednesday after presenting results from an "informational analysis" of the Phase III Prepare trial of its RSV F vaccine to prevent respiratory syncytial virus (RSV) in infants via maternal immunization. Data were...

Read the full 181 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >